Cargando…
Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date
Hepatocellular carcinoma (HCC) is the fastest rising cause of cancer-related death in the United States and carries a very poor prognosis, with a median survival time of <50% at 1 year for advanced disease. To date, sorafenib is the only therapy approved by the Food and Drug Administration for th...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118026/ https://www.ncbi.nlm.nih.gov/pubmed/27896243 http://dx.doi.org/10.2147/JHC.S106072 |